Cellectar Biosciences, Inc.
CLRBNext catalyst
Phase 3 Results
Get an email about CLRB's next catalysts
Track Cellectar Biosciences (CLRB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
CLRB Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.46 | FQ end Sep/2026 | Call: tbd
Phase 3 Results
Cellectar announced plans to initiate a Phase III trial in late Q4 2026 with a potential FDA approval for a Waldenström macroglobulinemia treatment targeted for the second half of 2027.
How CLRB's past catalysts played out
Market Overview
Stock performance and key metrics
NOV-002
Ovarian Cancer
NOV-205
Hepatitis C
Iopofosine I 131 single dose
Waldenstrom Macroglobulinemia
Iopofosine I 131 fractionated dose
Waldenstrom Macroglobulinemia
Iopofosine I 131 multiple dose
Waldenstrom Macroglobulinemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NOV-002 | Phase 3 | Ovarian Cancer | - | - |
NOV-205 | Phase 2 | Hepatitis C | - | - |
Iopofosine I 131 single dose | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
Iopofosine I 131 fractionated dose | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
Iopofosine I 131 multiple dose | Phase 2 | Waldenstrom Macroglobulinemia | - | - |
Hepatitis C
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Waldenstrom Macroglobulinemia
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Cellectar Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Cellectar Biosciences, Inc.'s (CLRB) pipeline across Phase 3, Phase 2. Its lead program is NOV-002 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cellectar Biosciences, Inc.'s next FDA catalyst?→
Cellectar Biosciences, Inc.'s (CLRB) next tracked catalyst is a Phase 3 readout expected June 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLRB biotech catalysts?→
Add CLRB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cellectar Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.